Myovant Sciences's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2022 was $-0.63.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.21.
Myovant Sciences's EPS (Diluted) for the
three
months ended in Mar. 2022 was $-0.63.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.21.
Myovant Sciences's EPS without NRI for the
three
months ended in Mar. 2022 was $-0.63.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -2.21.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Myovant Sciences EPS (Basic) Historical Data
The historical data trend for Myovant Sciences's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
EPS (Basic)
-2.41
-4.09
-3.37
-2.83
-2.22
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
EPS (Basic)
-0.89
-0.67
-0.23
-0.68
-0.63
Myovant Sciences EPS (Basic) Calculation
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Myovant Sciences's Basic EPS for the fiscal year that ended in Mar. 2022 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Myovant Sciences EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.53(4.26%) Volume: 397,916 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
